PTLA News and Press, Portola Pharmaceuticals Inc. From 03/01/19

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authoriz...

CLNY , CORE , EBIX , FL , KOP , NWN , PEGI , PTLA , SNH , SSP , STRA , TGNA , TRCO , WUBA , XRAY For Seeking Alpha's full earnings season calendar, click here . More news on: Colony Capital, Inc., Core-Mark Holding Company, Inc., Ebix Inc, Earnings news and commentary,...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Once again U.S.-China trade talks will be watched closely as reports filter in on a...

Noteworthy events during the week of February 24 - March 2 for healthcare investors. More news on: uniQure N.V., Bausch Health Companies Inc., CytomX Therapeutics, Healthcare stocks news, , Read more ...

– Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients – –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events Observed Among Patients Who Re-started Oral Anticoagulation Therapy – – Data Present...

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and full year ended December 31, 2018, and pr...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] have been accepted as a l...

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately. Mr. Koenig brings to his new role more than ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Like action? What a week ahead with a cavalcade of companies due to present across ...